Clinical Trial

MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma

Study acronym: EpLCART
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase II open-label, two-arm randomised non-comparative, multi-centre study to evaluate the efficacy of Epcor-only (Epcoritamab alone) or Epcor-R2 (Epcoritamab, lenalidomide and rituximab) as consolidation post anti-CD19 CAR T-cell therapy for patients that have responded by conventional criteria but who are at high risk of progression by virtue of being Minimal Residual Disease (MRD) positive as determined by a Circulating Tumour DNA (ctDNA) assay.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-05-09; most recent amendment 2025-06-04.
Status change: Not Yet Recruiting → Recruiting 2024-08-08
Trial Details
NCT Number NCT06414148
Lead Sponsor Peter MacCallum Cancer Centre, Australia
Collaborators: AbbVie
Conditions Relapsed/Refractory Large B-cell Lymphoma
Enrollment 40 participants
Start Date 2024-05-14
Primary Completion 2026-10 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2025-06-05